Tilray Brands (NASDAQ:TLRY) Stock Price Up 8.1% – Should You Buy?

Tilray Brands, Inc. (NASDAQ:TLRY) shares shot up 8.1% during trading on Wednesday . The company traded as high as $4.86 and last traded at $4.83. Approximately 5,162,259 shares traded hands during mid-day trading, an increase of 20% from the average daily volume of 4,302,896 shares. The stock had previously closed at $4.47.

Key Stories Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: A sector-wide rebound lifted Tilray alongside Canopy Growth and Aurora Cannabis, suggesting investors were buying depressed cannabis stocks. However, the rally has not reversed the company’s broader weakness, with TLRY still down sharply for the year. Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%
• Positive Sentiment: Tilray Medical welcomed new German guidance that provides more practical direction for prescribing standardized full-spectrum cannabis extracts. A clearer medical-cannabis framework could support physician adoption, patient access and Tilray’s European medical business. Tilray Medical Welcomes Progress in Germany’s Medical Cannabis Framework
• Positive Sentiment: Tilray’s UK expansion is being viewed as a potential growth catalyst, while its international operations and consumer brands provide investors with exposure beyond Canada’s challenged recreational market. Could Tilray Brands Gain From Its UK Push?
• Neutral Sentiment: BrewDog, Tilray’s craft-beer subsidiary, announced its 2026 Advent Calendar. The product supports brand visibility and seasonal sales but is unlikely to materially affect near-term valuation. BrewDog Unwraps Its 2026 Advent Calendar
• Negative Sentiment: Analysts and commentators caution that Tilray’s underlying challenges remain unresolved, including an uncertain cannabis market, regulatory complexity and weak profitability. The latest rally therefore looks primarily sentiment-driven rather than evidence of a fundamental turnaround. The Cannabis Story Is Getting Complicated

Analyst Ratings Changes

TLRY has been the subject of several recent analyst reports. TD Securities raised Tilray Brands to a “strong-buy” rating in a research note on Friday, July 31st. Wall Street Zen lowered Tilray Brands from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. TD Cowen lowered their price target on Tilray Brands from $7.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, July 14th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tilray Brands in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $11.00.

Tilray Brands Stock Performance

The firm’s fifty day moving average price is $4.50 and its 200 day moving average price is $5.86. The company has a current ratio of 2.21, a quick ratio of 1.37 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $657.85 million, a price-to-earnings ratio of -4.47 and a beta of 1.90.

Tilray Brands (NASDAQ:TLRY) last posted its quarterly earnings data on Tuesday, July 28th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.42). The company had revenue of $281.71 million for the quarter, compared to analysts’ expectations of $246.30 million. Tilray Brands had a negative return on equity of 7.76% and a negative net margin of 13.11%. Analysts forecast that Tilray Brands, Inc. will post -0.4 EPS for the current fiscal year.

Insider Activity at Tilray Brands

In other news, CFO Carl A. Merton acquired 10,000 shares of the company’s stock in a transaction dated Tuesday, August 4th. The stock was acquired at an average cost of $4.62 per share, with a total value of $46,200.00. Following the completion of the purchase, the chief financial officer owned 139,753 shares of the company’s stock, valued at $645,658.86. This represents a 7.71% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Insiders acquired 15,000 shares of company stock worth $69,225 in the last ninety days. Company insiders own 0.84% of the company’s stock.

Hedge Funds Weigh In On Tilray Brands

Hedge funds have recently bought and sold shares of the company. Hillsdale Investment Management Inc. acquired a new position in shares of Tilray Brands in the fourth quarter valued at approximately $4,855,000. IFP Advisors Inc lifted its holdings in Tilray Brands by 14.3% during the 4th quarter. IFP Advisors Inc now owns 60,318 shares of the company’s stock worth $545,000 after buying an additional 7,541 shares in the last quarter. State of New Jersey Common Pension Fund D acquired a new stake in Tilray Brands during the 4th quarter worth approximately $346,000. Essential Partners LLC boosted its position in Tilray Brands by 110,137.5% in the 1st quarter. Essential Partners LLC now owns 8,819 shares of the company’s stock valued at $57,000 after buying an additional 8,811 shares during the period. Finally, Entropy Technologies LP purchased a new position in Tilray Brands in the 1st quarter valued at approximately $123,000. Institutional investors and hedge funds own 9.35% of the company’s stock.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.